Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
24 Feb 2020
24 Feb 2020
Historique:
received:
02
12
2019
accepted:
12
02
2020
entrez:
2
5
2022
pubmed:
25
2
2020
medline:
25
2
2020
Statut:
epublish
Résumé
Therapeutic strategies for cancer involving immune checkpoint inhibitors (ICIs) have been gaining widespread attention, but their efficacy remains limited. Thus, combination of ICI therapies with other therapeutic modalities may be required to improve their outcomes. In this study, we examined the improved efficacy of a CHP nanogel-based vaccine delivery system after combination with ICI therapy. For this, we evaluated the therapeutic efficacy of combining an anti-PD-1 antibody as an ICI with an OVA antigen-complexed CHP nanogel vaccine delivery system in a mouse E.G7-OVA tumor model. Mice were subcutaneously inoculated with E.G7-OVA tumor cells on one side of the back, and subcutaneously injected with OVA or the OVA/CHP nanogel vaccine on the other side of the back. Anti-PD-1 antibody was administered at defined intervals. Tumor volume, immune responses, and tumor-infiltrating cells were evaluated. Mice treated with OVA vaccine alone showed weak tumor suppression compared with untreated control mice. Mice receiving combined OVA/CHP nanogel vaccine and anti-PD-1 antibody therapy exhibited strong tumor growth suppression and markedly improved survival, suggesting that PD-1 signaling blockade by the anti-PD-1 antibody enhanced the anti-tumor efficacy of the OVA vaccine. Furthermore, tumor-infiltrating cells and immune responses were increased in the combined therapy group. No serious side effects were observed for any of the treatments. Taken together, the immune system activation induced by the CHP nanogel vaccine was synergistically enhanced by the anti-PD-1 antibody. The present findings suggest the potential for enhanced therapeutic efficacy by combining the CHP nanogel vaccine delivery system with ICI therapy for various cancer types.
Identifiants
pubmed: 35497849
doi: 10.1039/c9ra10066k
pii: c9ra10066k
pmc: PMC9049940
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8074-8079Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Sci Rep. 2018 Nov 7;8(1):16464
pubmed: 30405172
ACS Nano. 2014 Sep 23;8(9):9209-18
pubmed: 25180962
Adv Drug Deliv Rev. 2015 Dec 1;95:65-76
pubmed: 26482187
Adv Sci (Weinh). 2019 Jan 13;6(6):1801847
pubmed: 30937265
Nat Commun. 2017 Nov 23;8(1):1747
pubmed: 29170511
J Clin Invest. 2019 Mar 1;129(3):1278-1294
pubmed: 30628894
Nat Rev Cancer. 2016 Apr;16(4):219-33
pubmed: 26965076
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Pharm Res. 2014 Oct;31(10):2563-82
pubmed: 24848341
Nat Rev Immunol. 2010 Nov;10(11):787-96
pubmed: 20948547
Cancer Immun. 2007 Apr 19;7:9
pubmed: 17441676
Nat Commun. 2019 May 2;10(1):2025
pubmed: 31048681
Cell Mol Immunol. 2017 Aug;14(8):675-684
pubmed: 27041637
Blood. 2007 Jun 15;109(12):5318-26
pubmed: 17339421
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Clin Cancer Res. 2006 Dec 15;12(24):7397-405
pubmed: 17189412
Nat Rev Immunol. 2014 Nov;14(11):768-74
pubmed: 25257362
Nat Mater. 2013 Nov;12(11):978-90
pubmed: 24150416
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
Nat Med. 2016 Dec;22(12):1402-1410
pubmed: 27775706
Immunity. 2018 Mar 20;48(3):417-433
pubmed: 29562193
Vaccines (Basel). 2015 Aug 27;3(3):662-85
pubmed: 26350600